TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03733379

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic placebo
Description: The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
Study: NCT03503604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion, 400 mg/m2 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion, 175 mg/m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, AUC=6 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, AUC=4 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
Study: NCT06084299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
Study: NCT03809689

Intervention type: OTHER
Group type: OTHER
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection

Intervention type: OTHER
Group type: OTHER
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection

Intervention type: OTHER
Group type: OTHER
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 82-Rb PET/CT as part of standard care, not a comparator
Description: 2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
Study: NCT04057521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Comprehensive care coordination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: Comprehensive care coordination.
Study: NCT03809689

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 82-Rb PET/CT as part of standard care, not a comparator
Description: 2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 82-Rb PET/CT as part of standard care, not a comparator
Description: 2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
Study: NCT00708890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivation to participate in TSG
Description: The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
Study: NCT03739281

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MR
Description: The included patients are imaged with PET/MR as part of the research protocol.
Study: NCT03690895

Intervention type: OTHER
Intervention: Retrospective survival analysis
Description: Kaplan-Meier model
Study: NCT00350844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
Study: NCT04247737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten free diet
Description: Participants keep a gluten free diet for six weeks
Study: NCT02797392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
Study: NCT02380911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions.
Study: NCT02744638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic yoghurt
Description: verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chemically acidified milk
Description: Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arilin
Description: 2 tablets Arilin 500mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arilin
Description: 2 tablets Arilin 500mg for 7 days
Study: NCT02816801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butler-Program 2.0
Description: Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
Study: NCT02100475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
Study: NCT04063969

Intervention type: OTHER
Intervention: Assessment of radiation safety climate
Description: The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140

Intervention type: OTHER
Intervention: Assessment of radiation safety behavior
Description: The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10

Intervention type: OTHER
Intervention: Assessment of radiation safety knowledge and motivation
Description: The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5

Intervention type: OTHER
Intervention: Data collection
Description: Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
Study: NCT04227093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Oral acetazolamide tablets of 250 mg taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken twice daily.
Study: NCT03739281

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: The included patients are imaged with PET/CT as part of normal clinical routine.
Study: NCT00949234

Intervention type: DRUG
Group type: OTHER
Intervention: tenofovir + emtricitabine, lopinavir/ritonavir
Description: The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily
Study: NCT02219529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE
Study: NCT00210314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose cytarabine

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study: NCT00547703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline 25mg capsule, orally administered, every night for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
Study: NCT03999307

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Description: LLLT will be applied in this group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless Corticopunture
Description: Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Typical orthodontic treatment with no LLLT or flapless corticopuncture
Study: NCT00576667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study: NCT04606797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine transdermal patches as per product monograph
Study: NCT01953380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: extended information
Study: NCT02111473

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study: NCT00201266

Intervention type: PROCEDURE
Intervention: Screening
Description: Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
Study: NCT02642172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITF (Inulin/OFS 75/25)
Description: Participants will consume 16 g/day ITF
Study: NCT01465646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Study: NCT02642172

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 16 g/day maltodextrin
Study: NCT04042506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: 480mg IV every 4 weeks
Study: NCT01465646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Study: NCT03298750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of ovarian tissue and mechanical stimulation
Description: he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.
Study: NCT00122343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
Study: NCT03758911

Intervention type: OTHER
Intervention: Semi-structured Interview
Study: NCT00949624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 60 mg BID continuous
Study: NCT04042506

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
Study: NCT03648099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor dance
Description: The dance group which involved pregnant women who performed the labor dance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: The music group involving pregnant women who were exposed to music.
Study: NCT02219529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gastroscopy
Study: NCT00166075

Intervention type: PROCEDURE
Intervention: Computer screen with community resource printout
Description: Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
Study: NCT01846156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
Study: NCT02603016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLSE compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maitake mushroom extract compound
Study: NCT01846156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
Study: NCT02603016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseng compound
Study: NCT01869933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-10X
Study: NCT00949624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 75 mg/m2 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 100 mg BID continuous
Study: NCT02079402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic crystalloids
Study: NCT02079402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloids
Study: NCT02941471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Stimulation
Description: Transabdominal interferential electrcial stimulation
Study: NCT01046175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-stacking with a manual resuscitator
Description: Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air-stacking with ventilator
Description: Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
Study: NCT02941471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS stimulation
Description: Transabdominal standard electrical stimulation
Study: NCT03936036

Intervention type: DRUG
Intervention: Linagliptin
Description: Linagliptin dispensing claim is used as the exposure

Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT03906799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Study: NCT01026753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refrigerator Magnet
Description: The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
Study: NCT01602822

Intervention type: DRUG
Group type: OTHER
Intervention: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Description: TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
Study: NCT01300715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar medial branch radiofrequency neurotomy
Description: the classic tunnel vision technique versus the alternative technique
Study: NCT04013906

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Description: Rotational atherectomy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Description: Rotational atherectomy
Study: NCT04028739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curmin
Description: curcumin 90mg/day cross-over

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curmin
Description: curcumin 90mg/day cross-over

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curmin
Description: curcumin 90mg/day cross-over
Study: NCT02570945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients
Study: NCT03208634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic intervention
Description: One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
Study: NCT01921504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea
Study: NCT00668811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248, Sutent
Description: Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.